Abstract: The present disclosure relates to a pre-5th-Generation (5G) or 5G communication system to be provided for supporting higher data rates Beyond 4th-Generation (4G) communication system such as Long Term Evolution (LTE).

Abstract: This application relates to the field of communication technologies, and discloses a user equipment route selection policy URSP determining method, a user equipment, and a network side device. The user equipment route selection policy URSP determining method in embodiments of this application includes the following steps: A user equipment obtains at least one first URSP. Each first URSP includes first indication information, or each first URSP includes a correspondence between the first URSP and the first indication information. The user equipment determines a target URSP from the at least one first URSP based on the first indication information or the correspondence.

Abstract: Disclosed in the present invention is a new triptolide derivative as shown in formula (I). Also disclosed in the present invention are a preparation method for the compound and the medical use thereof in preparation of anti-cancer drugs. Triptolide acrylate of the present invention and a pharmaceutically acceptable salt thereof have anti-cancer activity, and after animal in-vivo experiments, can effectively inhibit tumor growth in animals. A plurality of in-vitro experiments proves that same can significantly increase the protein expression quantity of p53, promote the apoptosis of tumor cells, effectively inhibit the growth of the tumor cells, and have the effect of inhibiting metastasis of cancer cells. More importantly, the toxicity of the compound to normal cells is less than that of triptolide.

Abstract: Disclosed in the present invention is a new triptolide derivative as shown in formula (I). Also disclosed in the present invention are a preparation method for the compound and the medical use thereof in preparation of anti-cancer drugs. Triptolide acrylate of the present invention and a pharmaceutically acceptable salt thereof have anti-cancer activity, and after animal in-vivo experiments, can effectively inhibit tumor growth in animals. A plurality of in-vitro experiments proves that same can significantly increase the protein expression quantity of p53, promote the apoptosis of tumor cells, effectively inhibit the growth of the tumor cells, and have the effect of inhibiting metastasis of cancer cells. More importantly, the toxicity of the compound to normal cells is less than that of triptolide.

Abstract: Disclosed is application of emodin in inhibiting amyloid ?-protein (A?) accumulation, improving cognitive and memory abilities, and reducing senile plaques. Alzheimer's disease (AD) is a neurodegenerative disease which is characterized in that nerve cell fibers are entangled. A? plaques are deposited, and a cognitive function is impaired to a pathological feature, and extracellular toxicity accumulation of A? is considered as one of main links of AD pathogenesis. In the present invention, it is discovered that emodin can obviously inhibit accumulation of an A?42 monomer and formation of fibers and inhibit formation of a ? secondary structure, can improve spatial memory learning ability of an AD mouse, and can obviously clear amyloid plaques in APP/PS1 double-transpenic AD model mouse brain tissues. It shows that emodin can be applied to treatment of AD, and research and development of related medicaments.